Literature DB >> 19214024

Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans.

Hong-Kyu Kim1, Joong-Yeol Park, Ki-Up Lee, Go-Eun Lee, Seong-Hoon Jeon, Jin-Ho Kim, Chul-Hee Kim.   

Abstract

BACKGROUND: Although the prevalence of nonalcoholic fatty liver disease (NAFLD) has been increasing, there have been few studies of long-term changes in NAFLD in large numbers of subjects. This study was performed to assess the long-term changes in severity of fatty liver and to analyze the association with changes in body weight and lifestyle factors.
METHODS: We analyzed lifestyle factors, biochemical data, and abdominal ultrasonography in subjects who underwent voluntary medical checkups at a 5-year interval. Fatty liver on ultrasonography was graded as normal, mild, moderate, or severe by the degree of echogenicity.
RESULTS: The analyzed population consisted of 2895 subjects of age 47+/-8.7 years (range, 20-79 years). Among the 1938 subjects who had normal livers at baseline, 374 subjects (19%) developed fatty liver 5 years later. Those who developed fatty liver showed more weight gain, increase of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (gamma-GT), and glucose levels during the 5-year period. Among the 930 subjects who had fatty liver at baseline, 263 (28%) subjects showed a decrease in grade and 209 (22%) progressed to a higher grade of fatty liver after 5 years. The group with a lower grade lost -2.2+/-4.3 kg of body weight from baseline, and reduction in hepatic steatosis grade was associated with decreased serum AST, ALT, triglycerides, gamma-GT, and fasting glucose levels.
CONCLUSIONS: Even a small weight reduction was associated with improvements in NAFLD and related metabolic abnormalities such as dyslipidemia and hyperglycemia. Subjects with fatty liver should be advised to lose weight through lifestyle modifications.

Entities:  

Mesh:

Year:  2009        PMID: 19214024     DOI: 10.1097/MAJ.0b013e3181812879

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  22 in total

1.  Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology.

Authors:  Yoshihisa Takahashi; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.

Authors:  Zhen-Ya Lu; Zhou Shao; Ya-Li Li; Muhuyati Wulasihan; Xin-Hua Chen
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

3.  Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.

Authors:  Kristin D Kistler; Elizabeth M Brunt; Jeanne M Clark; Anna Mae Diehl; James F Sallis; Jeffrey B Schwimmer
Journal:  Am J Gastroenterol       Date:  2011-01-04       Impact factor: 10.864

4.  The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease.

Authors:  Chuang-Yu Cao; Yu-Yuan Li; Yong-Jian Zhou; Yu-Qiang Nie; Yu-Jui Yvonne Wan
Journal:  Tohoku J Exp Med       Date:  2012-08       Impact factor: 1.848

5.  Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention.

Authors:  Valerio Nobili; Anna Alisi; Massimiliano Raponi
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

6.  Combination drug treatment in patients with non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2010-04-27

Review 7.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

Review 8.  Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials.

Authors:  Shira Zelber-Sagi; Justyna Godos; Federico Salomone
Journal:  Therap Adv Gastroenterol       Date:  2016-03-17       Impact factor: 4.409

9.  Revision and update on clinical practice guideline for liver cirrhosis.

Authors:  Ki Tae Suk; Soon Koo Baik; Jung Hwan Yoon; Jae Youn Cheong; Yong Han Paik; Chang Hyeong Lee; Young Seok Kim; Jin Woo Lee; Dong Joon Kim; Sung Won Cho; Seong Gyu Hwang; Joo Hyun Sohn; Moon Young Kim; Young Bae Kim; Jae Geun Kim; Yong Kyun Cho; Moon Seok Choi; Hyung Joon Kim; Hyun Woong Lee; Seung Up Kim; Ja Kyung Kim; Jin Young Choi; Dae Won Jun; Won Young Tak; Byung Seok Lee; Byoung Kuk Jang; Woo Jin Chung; Hong Soo Kim; Jae Young Jang; Soung Won Jeong; Sang Gyune Kim; Oh Sang Kwon; Young Kul Jung; Won Hyeok Choe; June Sung Lee; In Hee Kim; Jae Jun Shim; Gab Jin Cheon; Si Hyun Bae; Yeon Seok Seo; Dae Hee Choi; Se Jin Jang
Journal:  Korean J Hepatol       Date:  2012-03-22

Review 10.  Lean NAFLD: an underrecognized and challenging disorder in medicine.

Authors:  Sheila Maier; Amanda Wieland; Melanie Cree-Green; Kristen Nadeau; Shelby Sullivan; Miguel A Lanaspa; Richard J Johnson; Thomas Jensen
Journal:  Rev Endocr Metab Disord       Date:  2021-01-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.